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Abstract
Background: Standard-of-care therapies for treating pediatric medulloblastoma have long-term side effects, even in
children who are cured. One emerging modality of cancer therapy that could be equally effective without such
side effects would be chimeric antigen receptor (CAR) T cells. Knowing that human epidermal growth factor
receptor 2 (HER2) is overexpressed in many medulloblastomas and has been used as a CAR T target before, we
sought to evaluate the efficacy of more sophisticated anti-HER2 CAR T cells, as well as the feasibility and efficacy of
different routes of delivering these cells, for the treatment of pediatric medulloblastoma.
Methods: Daoy, D283 and D425 medulloblastoma cell lines were characterized by flow cytometry to evaluate HER2
expression. Anti-tumor efficacy of HER2-BBz-CAR T cells in vitro was performed using cytokine release and immune
cytotoxicity assays compared to control CD19 CAR T cells. In vivo, Daoy and D283 tumor cells were orthotopically
implanted in the posterior fossa of NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice and treated with regional or
intravenous HER2-BBz-CAR T cells or control CD19 CAR T cells. Non-human primates (NHPs) bearing ventricular and
lumbar reservoirs were treated with target autologous cells bearing extracellular HER2 followed by autologous
HER2-CAR T cells intraventricularly. Cerebrospinal fluid and blood were collected serially to measure the persistence
of delivered cells and cytokines.
Results: HER2-BBz-CAR T cells effectively clear medulloblastoma orthotopically implanted in the posterior fossa of
NSG mice via both regional and intravenous delivery in xenograft models. Intravenous delivery requires a log
higher dose compared to regional delivery. NHPs tolerated intraventricular delivery of autologous cells bearing
extracellular HER2 followed by HER2-BBz-CAR T cells without experiencing any systemic toxicity.
Conclusions: HER2-BBz-CAR T cells show excellent pre-clinical efficacy in vitro and in mouse medulloblastoma
models, and their intraventricular delivery is feasible and safe in NHPs. A clinical trial of HER2-BBz-CAR T cells directly
delivered into cerebrospinal fluid should be designed for patients with relapsed medulloblastoma.
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Background
Medulloblastoma is the most common type of malignant
pediatric brain tumor, comprising approximately 20% of
all new diagnoses in children between 0 and 19 years
old, but can occur in people of all ages [1]. Current
standard of care consists of gross total resection and in-
tensive chemotherapy, with or without radiation [1].
While overall survival with this treatment regimen ap-
proaches 75% at 5 years, it carries a high burden of mor-
bidity that includes neurocognitive loss, endocrine
abnormalities, hearing loss, growth problems and mor-
tality from secondary malignancies [2]. Recurrent disease
is usually fatal because of ineffective salvage therapies
[2], and studies exploring alternatives to traditional
chemotherapy, such as targeted inhibitors, have not been
successful [3]. The development of new modalities of
cancer therapy for medulloblastoma is therefore essen-
tial to the improvement of patient outcomes.
Receptor tyrosine-protein kinase ERBB2 (HER2) is a
well-known immunotherapy target that is overexpressed
in multiple adult and pediatric cancers [4–7], including
approximately 40% of medulloblastoma. HER2 surface
expression on medulloblastoma is associated with sig-
nificantly worse overall and progression free survival [8,
9]. Additionally, ERBB2 protein is not detected in nor-
mal brain [10], which has made it an attractive target for
therapy in these tumors. In the treatment of breast can-
cer, anti-HER2 monoclonal antibodies interfere with
HER2 signaling and cause cell death in cancer cells.
However, such antibodies have been found to be inef-
fective against medulloblastomas, partly due to the fact
that HER2 surface expression in medulloblastoma is
lower than in breast cancer and not associated with
HER2 gene amplification [11]. Thus, alternative modal-
ities have been explored to exploit HER2 overexpression,
among them chimeric antigen receptor (CAR) bearing T
cells.
CAR T cell therapy is a promising approach to target
HER2 expressing tumors, as it eliminates cancer cells
through direct T cell cytotoxicity rather than relying on
antibody-dependent cell-mediated cytotoxicity. T cells
bearing CARs combine the specificity of an antibody
with the cytolytic ability of a T cell and can effectively
kill tumor cells bearing a specific antigen [12]. CD19-
directed CAR T cells have produced dramatic responses
in patients with relapsed and refractory B cell malignan-
cies [13, 14]. Adoptive transfer of natural killer cells [15]
and CAR T cells [11] have both shown promise in
mouse models of medulloblastoma. In previous pre-
clinical studies, first generation HER2-CAR T cells con-
taining CD3 zeta signaling without a co-stimulatory sig-
naling domain caused only transient tumor regression in
an orthotopic xenograft mouse model of medulloblas-
toma [11]. However, newer generations of CAR T cells
incorporating co-stimulatory domains have increased
proliferation and persistence in other tumor models,
resulting in improved cytotoxic potential [12]. HER2-
CARs are currently being used in clinical trials for the
treatment of glioblastoma and sarcomas and have
proven to be safe and well-tolerated [16, 17].
Here, we show that second generation HER2-CAR T
cells containing the CD3 zeta and 4-1BB signaling motifs
have robust in-vitro antitumor activity against medullo-
blastoma cell lines, and eradicate tumors in multiple
orthotopic xenograft mouse models of medulloblastoma.
We demonstrate that very low doses of HER2-CAR T
cells are capable of inducing full and durable regression
of established CNS tumors when administered region-
ally. We also show that these CAR T cells persist at low
levels in the brain and peripheral blood of treated mice
for an extended period after tumor clearance. Lastly, we
show that intraventricular delivery of HER2-CAR T cells
in non-human primates (NHPs) is feasible without sys-
temic toxicity and may be an important method of deliv-
ery for some patients. This study provides clear evidence
of the efficacy of newer generation HER2-CAR T cell
therapy against medulloblastoma. Considering the lack
of effective salvage regimens for patients with relapsed
medulloblastoma, these findings should be rapidly trans-
lated into a clinical trial.
Methods
Blood donors and cell lines
The medulloblastoma cell lines Daoy and D283 were ob-
tained from American Type Culture Collection (ATCC)
and D425 originated in the laboratory of Dr. Darell Bigner
(Duke University Medical Center). The ependymoma 928
cell line originated in the laboratory of Dr. Nicholas K.
Foreman and was used as a positive control for HER2
surface expression. All cell lines were grown in EMEM
(ATCC) with 10% fetal calf serum (FCS) and 1%
penicillin-streptomycin-glutamine (PSG) (Life Technolo-
gies). All cell lines were verified with short tandem repeat
analysis and confirmed mycoplasma free. Cell lines were
transduced with a lentivirus containing green fluorescent
protein (GFP) and luciferase coding sequences that were
co-expressed under the human elongation factor-1 pro-
moter. Cells were flow sorted for GFP expression and then
single cell cloned. Human peripheral blood mononuclear
cells (PBMCs) were obtained from normal donors at the
National Institutes of Health Blood Bank under Institu-
tional Review Board approved protocols. T cells were
grown in AIM-V (Life Technologies) with 5% FCS and 1%
PSG. All cells were cultured at 37°C and 5% CO2.
Construction of chimeric antigen receptors genes
The 4D5 single chain variable fragment (scFv) specific
for HER2, derived from the monoclonal antibody
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trastuzumab, was generously provided by the Surgery
Branch at NIH. It was originally cloned into an MSGV
(mouse stem cell virus-based splice-gag vector) with a
CD3 zeta signaling domain and 4-1BB and CD28 costi-
mulatory motifs. The 4D5 scFv was subcloned into an
MSGV with a CD3 zeta signaling domain and 4-1BB
costimulatory motif (HER2-BBz CAR) (Fig. 1a). The
CD19-BBz-CAR, which utilizes an identical CD3 zeta
signaling domain and 4-1BB co-stimulatory motif as the
HER2-BBz-CAR, was generated as previously described
[18] and was used as controls in all in-vitro and mouse
experiments.
Retrovirus production and transduction of T cells
HER2-BBz-CAR and CD19-BBz-CAR-encoding retroviral
supernatants were produced via transient transfection of
the 293GP cell line (Clontech). 293GP cells were trans-
fected via Lipofectamine 2000 (Life Technologies) per
manufacturer protocols with CAR and RD114 envelope
protein encoding plasmids.
Monocyte depleted PBMCs were activated with anti-CD3/
CD28 beads (Life Technologies) at a 3:1 bead:cell ratio with
40 IU/ml rh-IL-2 for 3 days. Activated T cells were trans-
duced with retrovirus on days 3 and 4 using Retronectin
(Clontech) coated plates, and cultured in 300 IU/ml rh-IL-2.
Anti-CD3/CD28 beads were removed on day 5. Media
and IL-2 were changed every 2 days. Transduction effi-
ciencies were assessed by flow cytometry [19].
Flow cytometry
All samples were analyzed with an LSR Fortessa (BD
Bioscience) or Gallios 561(Beckman Coulter). Data were
analyzed using FlowJo software. CARs were detected
with biotinylated protein L (Pierce Protein Biology)
followed by streptavidin-conjugated fluorophore. Human
T cells obtained from mouse blood and brain were char-
acterized with human antibodies CD45 (HI30,
eBioscience), CD4 (OKT4, BioLegend), and CD8 (RPA-
T8, eBioscience). Cell line antigen expression was deter-
mined with anti-HER2 antibody (HER2Sense™645, red
fluorescently labeled trastuzumab).
Cytotoxicity and cytokine assays
Parental tumor cells were transfected with nuclear locat-
ing mCherry (Essen CellPlayer NucLight Red) and anti-
biotic selected. 5000 target tumor cells were seeded per
well in a 96-well plate and co-incubated with CAR T
cells or controls for 24 h at effector–to–target ratios
ranging from 10:1 to 2.5:1. Cells were cultured at 37°C
and 5% CO2 and monitored using an IncuCyte Zoom
(Essen BioScience). Images were captured hourly until
8 h and then at 4-h intervals from 4 separate regions per
well using a 10X objective. Each experiment was done in
triplicate.
Cytokine production by CAR T cells or controls was
evaluated by co-incubation with target tumor cells at a
1:1 ratio for 24 h. Supernatants were harvested and cyto-
kine levels measured using a human pro-inflammatory
multi-array panel (MesoScale Discovery).
In-vivo mouse studies
All animal studies were carried out under protocols ap-
proved by the NCI Bethesda Animal Care and Use Com-
mittee. Xenograft studies were performed using female
NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) from The
Jackson Laboratory aged 6–8 weeks with an average
weight of 30 g. Mice were anesthetized with 50 mg/kg
ketamine and 0.5 mg/kg dexmedetomidine by
intraperitoneal (IP) injection. The mice were
immobilized in a mouse stereotaxic device (Stoelting).
The head was shaved and scrubbed with 1% povidone-
iodine, then a 1 cm skin incision was made along the
midline and a burr hole was made using an 18G needle.
Cerebellar coordinates were − 2 from lambda, + 1 lat-
erally, and 3 mm deep from the surface of the skull.
Using a 28G needle mounted on a Hamilton syringe, lu-
ciferase expressing Daoy (5 X 104) or D283 (1 X 105)
cells in 5 ul were injected through the burr hole over the
course of 5 min. The needle was then slowly retracted
and the incision closed using 2–3 wound clips. Mice
were treated with 1 mg/kg atipamezole IP to reverse the
effects of dexmedetomidine. Buprenorphine 0.05 mg/kg
was injected subcutaneously for pain control.
For most experiments, mice were treated seven days
after tumor implantation and after confirmation of
tumor formation by bioluminescence. Mice were distrib-
uted randomly across treatment groups. Mice were
treated with either 2.5 X 106 T cells intravenously (IV)
via tail vein injection or 5 X 105 T cells in 5 ul
intratumorally (IT) to the same tumor coordinates. For
the experiments to determine the efficacy of treating
very established tumors, mice were treated 22 days after
tumor implantation and after confirmation of tumor
formation by bioluminescence with 5 X 106 T cells IV via
tail vein injection. Wound clips were removed 10 days
after placement. Peripheral blood was analyzed for T cell
persistence. Brains were harvested for additional analysis
of T cell persistence after euthanasia at the experimental
endpoint. Experimental endpoints were defined by
physical signs of distress such as weakness, paralysis,
wasting, or significant hair loss during the study or high
tumor burden as measured by bioluminescence imaging
(greater than 1 X 109 photons/s/cm2/sr).
Bioluminescence imaging
Isofluorane-anesthetized animals were imaged using the
IVIS system (IVIS, Xenogen) 10 min after 150 mg/kg D-
luciferin (Xenogen) was injected IP. Living Image
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Fig. 1 Construction and in vitro evaluation of HER2 CAR T cells. a To create anti-HER2 CAR T cells, the 4D5 anti-HER2 scFv was ligated into a retro-
viral backbone vector containing a CD3 zeta chain signaling domain and 4-1BB costimulatory domain. Human peripheral blood mononuclear cells
(PBMCs) from healthy donors were activated with anti-CD3/anti-CD28 beads on Day 0 and serially transduced with retrovirus containing the CAR
construct on days 2 and 3. Beads were removed on day 4 and T cells were allowed to expand until day 9–11, at which point CAR T cells were
harvested. Anti-HER2 CAR expression was assessed by Protein L staining and flow cytometry on Day 4. Representative Protein L staining results
are shown for mock transduced T cells, CD19 CAR T cells, and HER2 CAR T cells. b HER2 Expression was assessed for the DAOY, D283, and D425
human medulloblastoma cell lines via either qPCR (left) or flow cytometry using the trastuzumab-APC antibody (right). The 928 cell line was used
as a positive control for flow cytometry. c In a 24-h Incucyte Zoom assay, tumor cells were co-cultured with CD19 CAR or HER2 CAR transduced T
cells at the indicated ratios or with trastuzumab. Percent total live tumor cells was measured compared to 100% at time zero. The percentage of
live tumor cells at the 24 h time point was compared for each condition using a one-way ANOVA with Sidak’s correction for multiple hypothesis
testing. Statistics are shown for the comparison of HER2 CAR 2.5:1 and CD19 CAR 10:1 for all three lines, as well as the comparison of trastuzumab
and HER2 CAR 2.5:1 for D425. Denotion of “n.s” indicates a p value greater than 0.95. d Tumor cells were co-cultured for 24 h with CD19 CAR or
HER2 CAR transduced T cells at a 1:1 ratio. IFNγ, IL-2, and TNFα production was measured by a Meso Scale Discovery immunoassay kit, and com-
pared for each condition using multiple T tests with the Holm-Sidak correction
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software was used to quantify the photons emitted
from luciferase-expressing cells. Animals were imaged
to confirm tumor implantation and then imaged twice
weekly.
Mouse xenograft study design
All animals were treated with T cells after confirm-
ation of tumor engraftment by bioluminescence im-
aging. For animals that were euthanized to look for
human T cells in mouse tissues, the experimental end-
point was approximately 30 days after treatment with
T cells. All other xenograft studies were carried out
until the previously defined experimental endpoints
were reached.
Non-human primate (NHP) studies
All NHP studies were carried out under protocols ap-
proved by the NCI Bethesda Animal Care and Use Com-
mittee. Four adult male, healthy, non-tumor bearing
rhesus macaques (Macaca mulatta) ages 13–15 years,
weighing 10.5–14.7 kg, negative for SRV/SIV, and Her-
pes B viruses were used. The animals were cared for in
accordance with the National Research Council (NRC)
Guide for the Care and Use of Laboratory Animals. The
macaques used all had implanted CNS ventricular and
lumbar reservoirs. Animals were sedated (Ketamine, IM,
10 mg/kg, Vedco Inc.) prior to treatment.
NHP study design
Rhesus PBMCs collected by venipuncture were isolated
using a FICOLL gradient. Cells were cultured in AIM-V
with 5% FCS and activated with rhesus specific anti-CD3
antibody (BD Bioscience, 20 ng/ml), anti-CD28 antibody
(BD Bioscience, 1μg/ml), and 40 IU/ml rh-IL-2. Acti-
vated T cells were then transduced with a retrovirus to
co-express HER2-BBz-CAR and blue fluorescent protein
(BFP) on days 3 and 4 using Retronectin (Takara) coated
plates, and cultured in 300 IU/ml recombinant human
IL-2. Media and IL-2 were changed every 2 days. Trans-
duction efficiencies were assessed by flow cytometry
using both BFP and protein L.
Separately, T cells from NHPs were transduced with a
retrovirus (MSGV) encoding truncated HER2 and GFP
to create autologous cells with human HER2 surface ex-
pression (T-HER2). Transduction efficiencies were
assessed by flow cytometry using both GFP and anti-
HER2 antibodies.
1.5 X 105 autologous T-HER2 cells in 0.5 ml sterile
PBS were instilled over 1 min into a lateral ventricle res-
ervoir in each NHP. Thirty minutes later, all animals
were treated with 1.5 X 105 autologous HER2-CAR T
cells in 0.5 ml sterile PBS over 1 min into the same ven-
tricular reservoir. Cerebrospinal fluid (CSF) was col-
lected 1, 3, and 7 days after treatment through a lumbar
reservoir. Peripheral blood was collected at the same
time-points. CSF and blood were analyzed by flow cy-
tometry for persistence of both T-HER2 and HER2-CAR
T cells. CSF and plasma were analyzed for cytokines
using the NHP Proinflammatory Panel 1 kit (MesoScale
Discovery).
Statistics
Prism 6 software was utilized for statistical analysis.
Cytokine concentrations and immune cytotoxicity were
analyzed using a one-way ANOVA with Bonferroni’s
correction for multiple comparisons. Comparison of T
cells found in mouse blood/tissues across groups was
done with using the Mann-Whitney nonparametric
unpaired U-test. Xenograft growth curves were com-
pared using Living Image software to quantify tumor
size for individual mice and then analyzed. Lumines-
cence values at each time point were converted to log
form and linear regression was used to find a curve
of best fit for each treatment group. The slopes of
these curves were then compared in a pairwise fashion
to look for differences in the overall rate of tumor
growth [20].
Results
HER2-BBz-CAR T cells kill medulloblastoma cells in-vitro
and produce effector cytokines
Medulloblastoma cell lines Daoy, D283, and D425 were
examined for HER2 expression by flow cytometry. Daoy
and D283 both exhibited HER2 surface expression, while
the D425 cell line exhibited no expression of HER2 (Fig.
1b) and served as a negative control. Ependymoma 928
cell line exhibited HER2 surface expression and served
as a positive control. Second generation CARs contain a
single co-stimulatory domain in addition to the CD3
zeta signaling domain. We chose to utilize the 4-1BB
(CD137) co-stimulatory domain, as previous work has
shown it to be superior in reducing T cell exhaustion
and enhancing T cell persistence compared to CD28 [19,
21]. HER2-BBz-CAR and CD19-BBZ-CAR T cells were
generated with transduction efficiencies between 40 and
80% (Fig. 1a). Additional characterization of HER2-BBz-
CAR T cell subtype, as well as activation and exhaustion
markers are displayed in Additional file 1: Figure S1.
There was no significant difference in T cell phenotype
when comparing HER2-BBZ-CAR T cells to non-
transduced, activated T cells, designated as mock.
Using CD19-BBz-CAR T cells and D425 cells as nega-
tive controls, HER2-CAR T cell cytotoxicity towards
Daoy, D283, and D425 was assessed using an Incucyte
Zoom assay over a 24-h period at an effector to target
(E:T) ratio of 10:1 to 2.5:1. HER2-BBz-CAR T cells dem-
onstrated significant killing of Daoy and D283, not
D425, even at low E:T ratios, and there was no
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cytotoxicity observed from either CD19-BBZ CAR T
cells or trastuzumab (Fig. 1d), which is consistent with
prior reports [11]. This data suggests that the HER2-
BBz-CAR confers specific killing activity against HER2-
positive medulloblastomas.
To assess cytokine production by T cells, we per-
formed a 24-h co-culture assay of HER2-BBz-CAR T
cells or CD19-BBz-CAR T cells with either Daoy, D283,
or D425 cells at an E:T ratio of 1:1. Supernatants from
these cultures were then analyzed for IFNγ, IL-2, and
TNFα concentration by multiplex array. HER2-BBz-CAR
T cells produced significantly higher levels of IFNγ, IL-2,
and TNFα in response to Daoy and D283 compared
to CD19-BBz-CAR T cells. Additionally, HER2-BBz-
CAR T cells did not produce significant levels of any
cytokine when co-incubated with D425 medulloblas-
toma cells (Fig. 1e). These findings support specific
HER2 antigen recognition by and activation of HER2-
BBz-CAR T cells in the presence of HER2-bearing
medulloblastomas.
Intratumorally delivered HER2-BBz-CAR T cells eliminate
medulloblastoma in murine xenografts
To create our mouse xenografts, Daoy cells were stably
transduced with a GFP-luciferase lentiviral construct
(Daoy-GL) to allow for the tracking of tumor growth over
time via bioluminescence (Fig. 2a). Daoy-GL cells were
flow sorted and then single cell cloned to ensure purity of
the transduced population. 5 X 104 Daoy-GL cells were
injected into the cerebella of NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (NSG) immunodeficient mice and allowed
to grow for one week (Fig. 2a) before T cell treatment.
Impaired CAR T cell trafficking from the blood to
tumor is one of the major limitations of CAR T cell ther-
apy in solid tumors [22]. We hypothesized that adminis-
tering CAR T cells directly to the tumor site would
eliminate this issue and would require significantly fewer
CAR T cells to achieve the same response as intraven-
ously administered CAR T cells. This approach has been
used previously with limited success [11], albeit with a
first-generation CAR. 5 X 105 human HER2-BBz-CAR T
cells or CD19-BBz-CAR T cells were delivered IT 7 days
following tumor cell injection, after which tumor
growth was followed via bioluminescent imaging (Fig. 2b;
Additional file 3: Figure S3a).
As predicted, mice treated with IT-delivered HER2-
BBz-CAR T cells experienced complete tumor regression
within 7–10 days and did not relapse for the duration of
the experiments. By contrast, mice treated with IT-
delivered CD19-BBz-CAR T cells experienced rapid
tumor progression requiring euthanasia at approximately
four weeks (Fig. 2b and c) (n = 20) and had evidence of
tumor upon immunohistochemical examination of the
brain post-mortem (Additional file 2: Figure S2A).
Regional delivery of HER2-BBz-CAR T cells is more
efficient in medulloblastoma xenografts than intravenous
treatment
We next sought to examine the efficacy of IV delivery of
HER2-BBz-CAR T cells in medulloblastoma-bearing
mice. After establishing Daoy-GL tumors as before, ei-
ther 5 X 105 or 2.5 X 106 HER2-BBz-CAR T cells or 2.5
X 106 CD19-BBz-CAR T cells were injected IV and mice
were followed by bioluminescence (Fig. 3a).
Following an initial, short-term regression, tumors
progressed in mice treated intravenously with 5 X 105
HER2-BBz-CAR T cells (Fig. 3b and c). This is in con-
trast to the complete resolution of tumors in mice
treated with the same dose IT (Fig. 2b; Additional file 3:
Figure S3a). In order to produce complete regression of
tumor, a five-fold higher cell dose (2.5 X 106) was
required when given IV versus IT. CD19-BBz-CAR T
cells had no significant effect on tumor growth (Fig. 3b
and c) (n = 30) and euthanized mice had evidence of
tumor on histology (Additional file 2: Figure S2B).
These results demonstrate that IV administration of
HER2-BBz-CAR T cells at the same cell dose is less ef-
fective at controlling tumor growth than IT administra-
tion and that higher doses of CAR T cells are required
for an equivalent level of disease control when given IV.
HER2-BBz-CAR T cells eliminate medulloblastoma in a
high-risk murine xenograft model
To explore the broad applicability of our observations in
medulloblastoma, we established a second xenograft
mouse model using the D283 cell line. This cell line
shows characteristics of the Group 3 and 4 subgroups of
medulloblastoma, which have a worse prognosis than the
Sonic Hedgehog (SHH) subgroup represented by the Daoy
cell line [23]. D283 cells were stably modified with GFP-
luciferase (D283-GL). We injected 5 X 104 D283-GL into
the cerebella of NSG mice as previously described, and
tumor engraftment was confirmed by bioluminescent im-
aging at one week. HER2-BBz or CD19-BBz-CAR T cells
were then delivered either IT (5 X 105 CAR T cells) or IV
(2.5 X 106 CAR T cells) (Fig. 4a) (n = 36).
IT delivered HER2-BBZ-CAR T cells at this very low
dose produced complete regression of the majority of tu-
mors, similar to the effect seen in the Daoy-GL model
(Fig. 4b and c; Additional file 3: Figure S3c). IV delivery
of HER2-BBz-CAR T cells at the dose that produced
complete Daoy-GL tumor regression (Fig. 3b; Additional
file 3: Figure S3b) was sufficient to eliminate D283-GL
tumors, and both IT- and IV-delivered HER2-BBz-CAR
T cells were significantly more effective than CD19-CAR
T cells (Fig. 4b and c; Additional file 3: Figure S3c). To-
gether, these observations in Daoy and D283 xenograft
models suggest that HER2-BBz-CAR T cells are likely to
be effective across a broad array of medulloblastomas
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with HER2 surface expression, regardless of their mo-
lecular subgroup.
HER2-BBz-CAR T cells eliminate well-established
medulloblastoma in a murine xenograft model
After observing the potent anti-tumor effects of HER2-
BBz-CAR T cells on medulloblastoma xenografts in pre-
vious experiments, we wanted to test whether or not
these cells could produce responses in larger, more
established tumors. To do so, we delayed CAR T cell
treatment from 7 days after tumor cell injection to
22 days. Between these time-points, tumor luminescence
was regularly monitored and treatment was started when
the average tumor size of each group of mice
approached 2 X 107 p/s/cm2/sr or approximately 10-fold
higher than previous experiments. Since the burr hole
created to deliver tumor cells had closed by this point,
CAR T cells were administered by IV route only. To
a
b
d
c
Fig. 2 Intratumoral administration of HER2 CAR T cells effectively treats medulloblastoma in an orthotopic model. a Outline of experimental
setup. DAOY human medulloblastoma cells were transduced with lentivirus containing a GFP-Luciferase construct to facilitate in vivo study. Ex-
ample DAOY-GL GFP expression is shown by flow cytometry. For the experiments, NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were given
tumor and treated with human CAR T cells intratumorally (IT) as shown. Bioluminescent imaging was performed using a Xenogen IVIS apparatus
twice per week. b Tumor growth curves for NSG mice treated with either HER2 and CD19 CAR T cells intratumorally on Day 0. Results are shown
for two experiments using T cells from two separate donors. Indicated doses correspond to the number of human CAR+ T cells infused into each
animal. Error bars represent standard error of the mean. For shown statistics, data were normalized, linear regressions fitted to the normalized
data, and slopes were compared using an ANOVA test. c Bioluminescent images from selected timepoints during the experiments. Indicated
doses represent number of CAR positive T cells injected per mouse. d Brain and peripheral blood were harvested from mice on day 22 post-
treatment and analyzed by flow cytometry. The presence of human CAR+ T cells was assessed by CD45 and Protein-L staining. Total amounts of
human CAR T cells in the brain and relative concentrations in the peripheral blood for each group were compared using Mann-Whitney non-
parametric statistical tests
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compensate for the higher initial tumor burden, a higher
dose of 5 X 106 HER2-BBz or CD19-BBz-CAR T cells
were administered IV and tumor size post-treatment was
measured twice weekly by bioluminescence (Fig. 5a).
As expected, mice given CD19-BBz-CAR T cells expe-
rienced rapid tumor progression and had to be eutha-
nized due to excessive tumor burden 15 days following
treatment (37 days after tumor implantation). In con-
trast, mice given HER2-BBz-CAR T cells experienced
rapid tumor regression within 1 to 5 days, with complete
regression of all tumors observed by day 5 (Fig. 5b and c;
Additional file 3: Figure S3d) (n = 14). The increased po-
tency of this effect in comparison to the other experi-
ments is likely explained by the increased dose of T cells
administered, rather than a biological effect unique to the
higher tumor burden setting. These mice remained
healthy and clear of tumor during regular follow-up, for a
total of 36 days post-treatment, and had a significantly
a
b c
d
Fig. 3 Intravenous HER2 CAR T cells can effectively treat medulloblastoma, but requires a higher dose level. a Outline of experimental setup.
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were given tumor and treated with human CAR T cells IV as shown, at one of two dose levels.
Bioluminescent imaging was performed using a Xenogen IVIS apparatus twice per week. b Tumor growth curves for NSG mice treated with
either HER2 and CD19 CAR T cells IV at both high and low dose levels on Day 0. Results are shown for two experiments using T cells from two
separate donors. Error bars represent standard error of the mean. For shown statistics, linear regressions were fitted to each curve and slopes
were compared using an ANOVA test. c Bioluminescent images from selected timepoints during the experiments. Indicated doses represent
number of CAR positive T cells injected per mouse. d Brain and peripheral blood were harvested from mice on day 22 post- treatment and
analyzed by flow cytometry. Total amounts of human CAR T cells in the brain and relative concentrations in the peripheral blood were measured
and compared as previously described in Fig. 2
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prolonged survival (Fig. 5d). Mice were euthanized due
to progressive signs of xenogeneic graft versus host
disease, a known complication of using human CAR T
cells in murine xenografts [24]. These results further
strengthen our previous findings that treatment with
HER2-BBz-CAR T cells leads to complete regression of
orthotopic medulloblastoma, including very established
tumors.
HER2-BBz-CAR T cells persist at low levels in the brain
and peripheral blood
After observing the effect of HER2-BBz-CAR T cells on
established medulloblastoma xenografts, we wanted to
determine whether or not these T cells are capable of
persistence in these animals. Thirty days after CAR T
cell injection (IV or IT), mice were euthanized and brain
and peripheral blood were obtained. Single cell suspen-
sions were generated from the brain and peripheral
blood of each mouse and analyzed by flow cytometry for
the human lymphocyte markers CD45, CD4 and CD8,
as well as Protein L to detect expression of the CAR.
We found persistence of CAR T cells in the blood and
brain of mice treated regionally and intravenously with
CAR T cells (Figs. 2d and 3d). We found that there was
a trend towards greater persistence of HER2-BBz CAR-T
cells in the brain when administered intratumorally as
compared to CD19-BBz CAR-T cells, but overall there
were no statistically significant differences. Higher dose
levels of CAR-T cells administered intravenously also
seemed to be associated with greater persistence in both
the brain and peripheral blood, but this effect was only
significant in the case of CD19-BBz CAR T cells. Most
likely, an immunocompromised, lymphodeplete NSG
mouse is simply not an appropriate model to differenti-
ate persistence between different CAR T cells and the
routes of administration since unmodified human T cells
engraft in NSG mice regardless of the presence of a tar-
get antigen [24].
HER2-BBz-CAR T cells can be safely administered via an
intraventricular route in non-human primates (NHPs)
Given the concern for on-target, off-tumor systemic tox-
icity of HER2-directed CAR T cells [25] and the propen-
sity for medulloblastoma to metastasize along the
leptomeninges of the brain and spinal cord, intraventric-
ular delivery of HER2-BBz-CAR T cells may be preferred
over IV administration. To elucidate the kinetics and
compartmentalization resulting from intraventricular
HER2-BBz-CAR T cell delivery, NHPs bearing lateral
ventricle and lumbar reservoirs were employed. These
animals are excellent models for anti-HER2 therapeutic
testing due to the fact that rhesus macaques have 98%
homology to human receptor tyrosine protein kinase
ERBB2 [26], and trastuzumab, the monoclonal antibody
a
b c
Fig. 4 HER2 CAR T cells can effectively treat medulloblastoma in a second orthotopic model. a Outline of experimental setup. NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (NSG) mice were given tumor and treated with human CAR T cells IV or IT as shown, at one of two dose levels. Bioluminescent
imaging was performed using a Xenogen IVIS apparatus twice per week. b Tumor growth curves for NSG mice with previously described
treatments on Day 0. Error bars represent standard error of the mean. For shown statistics, linear regressions were fitted to each curve and slopes
were compared using an ANOVA test. c BLI images of mice from each group at selected timepoints. Indicated doses represent number of CAR
positive T cells injected per mouse
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that the HER2-BBZ-CAR T cell derives its specificity
from, recognizes a receptor on NHP epithelial cells [27].
Autologous rhesus T cells modified to express trun-
cated HER2 (T-HER2) were administered intraventricu-
larly to serve as a target for HER2-BBz-CAR T cells (n =
4). Transduction efficiencies for T-HER2 and HER2-
BBz-CAR T cells ranged from 45 to 90% (Fig. 6a). 1.5 X
105 T-HER2 cells were infused into a ventricular
reservoir and followed thirty minutes later by the
infusion of 1.5 X 105 autologous HER2-BBz-CAR rhesus
T cells. All animals had blood counts and chemistries at
baseline and then every other day; all values were within
normal limits. A standardized neurological assessment
was performed at baseline and then daily, and subjects
showed no changes from baseline. CSF from the lumbar
reservoir and plasma were sampled prior to cell delivery
and 1, 3, and 7 days later. T cells expressing T-HER2
and HER2-BBz-CAR were detected in the CSF of one
animal 24 h after treatment (Fig. 6b). Increases in IL-6
and IL-2 were detected in the CSF of most animals
(Fig. 6c). Increased IL-2 suggests antigen recognition
of the truncated HER2 protein by the HER2-BBz-
CAR T cells. No T cells expressing truncated HER2
or HER2-BBz-CAR and no elevated cytokines were
detected in the blood or plasma of treated animals
(data not shown).
a
b
d
c
Fig. 5 HER2 CAR T cells can effectively treat large, established medulloblastoma xenografts. a Outline of experimental setup. NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (NSG) mice were given tumor on Day 0 and tumor were allowed to grow until day 22. Mice were treated with 5e6 HER2-BBz CAR
T cells or CD19 CAR T cells on Day 22 and tumor growth was monitored by regular BLI imaging for approximately five weeks. Remaining mice
were then placed under long-term observation for tumor recurrence. Bioluminescent imaging was performed using a Xenogen IVIS apparatus. b
Tumor growth curves for NSG mice with previously described treatments applied on Day 0. Error bars represent standard error of the mean. For
statistics, linear regressions were fitted to each curve and slopes were compared using an ANOVA test. c BLI images of mice from each group at
selected timepoints. Indicated doses represent number of CAR positive T cells injected per mouse. d Overall survival of mice from each group.
HER2 CAR T cell-treated mice were euthanized on Day 37 post-treatment due to animal protocol restrictions, but had no observable tumors (data
not shown)
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Discussion
Prior pre-clinical studies of HER2-directed CAR T cells
for medulloblastoma had limited efficacy primarily due
to reliance on first-generation, CD3 zeta constructs [11].
Multiple second-generation CD19 CAR clinical trials
utilizing 41BB or CD28 co-stimulatory domains with
CD3 zeta have resulted in excellent clinical responses in
patients with B cell malignancies [13, 14, 28–33]; 41BB
co-stimulation results in longer persistence of CAR T
cells in some patients and murine studies directly com-
paring 41BB and CD28 co-stimulatory domains demon-
strate this [18]. A Phase I clinical trial of intravenously
administered HER2-CD28-CD3 zeta CAR modified
virus-specific T cells in patients with glioblastoma
showed few and limited responses [17]. We investigated
the efficacy of targeting HER2-expressing medulloblas-
toma using a modern CAR T cell via both IV and re-
gional routes in mice. We chose a second-generation
construct utilizing 4-1BB co-stimulation because of its
proven improved persistence in clinical trials and pub-
lished literature showing potent T cell activation and de-
creased, potential for T cell exhaustion [19].
We showed that human HER2-BBz-CAR T cells could
eliminate human medulloblastoma cells both in-vitro and
in mouse models of medulloblastoma. We also demon-
strated that HER2-BBz-CAR T cells produce significant
a
c
b
Fig. 6 HER2-CAR T cells administered intrathecally to non-human primates (NHP) did not cause toxicity. a Flow cytometry of truncated HER2 ex-
pression (left) and HER2 CAR expression (right) in NHP T cells prior to infusion. The transduction efficiency for truncated HER2 and HER2 CAR
ranged from 45 to 90% in all cell cultures. b Flow cytometry of truncated HER2 expression (left) and HER2 CAR expression (right) in T cells from
the cerebrospinal fluid (CSF) of NHP ZE32 on Day 1 after infusion. T-HER2 and HER2 CAR T cells were not detected in the other three animals, nor
were appreciable levels detected after Day 1 in animal ZE32. c Summary of CSF cytokine levels after infusion of T-HER2 target cells and HER2 CAR
T cells. Separate time courses of cytokine measurements, performed by ELISA, are shown for each animal in the experiment. Increases in IL-2 and
IL-6 were detected in the CSF of most animals, suggesting antigen recognition of the truncated HER2 protein by the HER2 CAR T cells. IL-8, IL-10,
and IL-1β were also tested for, but were undetectable in all samples
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levels of inflammatory cytokines during co-culture with
medulloblastoma, which is a key determinant of a success-
ful anti-tumor T cell response in humans [34]. Further-
more, we found that HER2-BBz-CAR T cells could fully
eliminate even very large, established tumors. Together,
these data indicate that HER2-BBz-CAR T cells possess
highly potent anti-tumor activity in medulloblastoma.
Tumor responses from HER2-BBz-CAR T cells were
observed regardless of the route of administration,
though a log fewer CAR T cells were required to achieve
the same effect when given regionally versus IV. Suc-
cessful regional delivery of a lower but equally as effect-
ive CAR T cell dose may mitigate on-target, off-tumor
systemic toxicity and/or cytokine release syndrome [35].
This route is potentially beneficial for patients with dis-
ease localized to one compartment.
To evaluate the feasibility of intraventricular CAR T
cell delivery, and explore whether this route would result
in systemic toxicity, we utilized NHPs with existing ven-
tricular and lumbar reservoirs. Since tumor lines cannot
be introduced to these animals, we chose to modify rhe-
sus autologous T cells with the extracellular domain of
HER2 to serve as targets of the CAR T cells. All but one
animal displayed an elevation of IL-6 in the CSF after in-
fusion of autologous T cells. IL-6 is not produced dir-
ectly by the CAR T cell in-vitro (data not shown) but
rather directly by or after interaction with endogenous
antigen presenting cells [36], suggesting recruitment of
the NHP’s immune system after CAR T cell infusion. El-
evated IL-2 was measured in 3 out of 4 animals, which
also suggests recognition of T-HER2 cells by HER2-CAR
T cells. Interestingly, only one animal had persistence of
T-HER2 and HER2-CAR T cells at 24 h and no elevation
of IL-2, which suggests a failure of the HER2-CAR T
cells to recognize the T-HER2 targets in this animal. Im-
portantly, no systemic exposure of HER2-BBz-CAR T
cells was found in any animal and plasma showed no
significantly elevated inflammatory cytokines. We there-
fore conclude that intraventricular delivery of HER2-
BBz-CAR T cells is feasible and, at the doses studied, did
not result in significant systemic exposure or toxicity.
There are limitations to our study that bear discussion.
Though the NSG mouse model is an excellent pre-
clinical tool for assessing the interactions between hu-
man tumor cells and human T cells, it does not capture
the interaction of these cells in the context of the human
immune system or tumor microenvironment. Second,
we utilized medulloblastoma cell lines instead of patient
derived tumor xenografts. We made this choice due to
the greater flexibility allowed in working with cell cul-
tures to perform correlative in-vitro assays and the abil-
ity to transduce cell lines with GFP and luciferase to
facilitate in-vivo identification. Though these cell lines
may be less representative of the tumor biology seen in
patients, a key advantage of CAR T cell therapy efficacy
is that it primarily requires only that the target of the
CAR be expressed on the cell surface, meaning that cell
line models can be more appropriate for testing these
types of therapies than in other cases.
A third limitation of our study surrounds the blood-
brain-barrier (BBB) in mice and the propensity of T cells
to cross that barrier. Sampson, et al. demonstrated that
IV administered murine EGFRvIII-CAR T cells can ef-
fectively clear orthotopic murine glioblastoma in the
forebrain of immunocompetent mice [37]. However, an-
other group showed only a reduction rather than clear-
ance of human glioblastoma tumors following IV
administration of human EGFRvIII-CAR T cells [38].
This is consistent with an earlier study showing the fail-
ure of IV-delivered, second generation human EphA2-
CAR T cells to cause any tumor regression of human gli-
oma orthotopically implanted in the brain of SCID (se-
vere combined immunodeficiency) mice [39]. A recent
publication of a human IL13rα2-CAR T cell only studied
regional delivery in an orthotopic human glioma mouse
model, citing the previous failures of IV administered
cells in clearing tumors in mouse brain, hypothesizing
that these failures were due to the inability of human T
cells to cross the murine BBB [40].
In our study, IV-administered HER2-BBz-CAR T cells
in sufficient doses are effective at eliminating stereotac-
tically implanted medulloblastoma in the posterior fossa
of xenografts. The initial injection of tumor cells into
the brain certainly disrupts the BBB, which may permit
translocation of CAR T cells several days later. However,
it is possible that CAR T cells are not impeded by the
BBB in any system. A functional lymphatic system in the
CNS has been described in mice [41] and, in a pivotal
Phase I study of CD19-directed CAR T cells in children
and young adults with acute lymphoblastic leukemia,
two patients with CNS leukemia had complete responses
in the CSF from a single IV dose of CAR T cells [13]. So,
while others have shown limited efficacy of IV dosing in
animals, IV administration of HER2-BBz CAR T cells for
medulloblastoma may be effective and could be explored
in human trials should intraventricular delivery prove
not to be effective.
The principal concern of systemically-administered
HER2-CAR T cells stems from potential on-target but
off-tumor cytotoxicity, especially in vital organs. A third
generation HER2-CAR T cell trial was stopped after the
first patient died within days after infusion of cells in
2010 [25]. It was initially hypothesized that the cause of
death was due to low levels of HER2 expression found
on heart and lung, but the safety and tolerability demon-
strated in newer HER2-directed CAR T cell trials would
seem to refute this hypothesis. HER2 has been targeted
with second generation CAR T cell therapies in patients
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with sarcoma and glioblastoma without significant tox-
icity [16, 17]. The biggest differences between these
studies were dose of CAR T cells infused, generation of
CAR employed, the use of a high-dose lymphodepleting
preparative regimen, and concurrent high-dose of IL-2
given with the cell infusion [25]. Cytokine release syn-
drome (CRS), a known life-threatening complication of
adoptive cell therapy resulting from the excessive release
of inflammatory cytokines by supra-physiologically acti-
vated immune cells, can unfold within hours to days
after cell infusion, consistent with the rapid onset of life-
threatening symptoms observed in the 2010 patient [42].
Our understanding of the pathophysiology and manage-
ment of CRS has increased significantly since this inci-
dent as more patients have been treated with adoptive
cell therapies [42]. Careful consideration of dosing and
lymphodepleting regimens coupled with timely interven-
tion with anti-cytokine drugs have made CAR T cell
therapy safer and more feasible for clinical investigation.
Conclusions
Children and adults with relapsed medulloblastoma have
a dismal prognosis even with aggressive therapy. Given
our data, advances in the understanding of CAR T cell
therapies, and the recently published case report of one
patient who safely received intraventricular IL13Rα2-
targeted CAR T cells [43], intraventricular delivery of
HER2-BBz-CAR T cells starting at a low-dose using care-
ful dose-escalation without a systemic lymphodepleting
regimen is a rational approach to translate this promising
therapy to patients with relapsed medulloblastoma.
Additional files
Additional file 1: Figure S1. Characterization of HER2 CAR T cell
phenotype. Human T cells were either mock transduced or transduced
with HER2 CAR as previously described in Methods. Cells were taken
from culture on Day 7 and stained for CD4, CD8, and either a panel of
markers of T cell activation (A) or a panel of markers of T cell exhaustion
(B). CAR+ T cells were identified by Protein-L staining as previously shown
in Fig. 1. Histograms for each population of T cells are shown above, as
well as the relevant FMO controls. (PPTX 389 kb)
Additional file 2: Figure S2. Medulloblastoma xenograft histology.
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were injected with
DAOY-GL tumor cells, as described in Methods, and treated with human
CD19 CAR T cells intratumorally (A) or intravenously (B). Mice were
euthanized at day 22 post-treatment and brain tissue was collected for
histology. Brains were sectioned and stained using H&E. Images were
taken using a digital slide scanner at 10X magnification, with
representative results shown above. DAOY-GL cells mainly formed tumors
along the periphery of the cerebellum (indicated by black arrows), but
can also be seen infiltrating into the parenchyma adjacent to normal
cerebellar cells (indicated by red arrow). (PPTX 5146 kb)
Additional file 3: Figure S3. Linear regression data used for calculating
statistics from Figs. 2, 3, 4, and 5. Data is presented as spider plots, with
each line representing data from an individual mouse, and linear
regression lines and equations overlaid. Fig. 2b. Fig. 3b. Fig. 4b. Fig. 5b.
(PPTX 274 kb)
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